Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)

XyloCor Therapeutics

Status and phase: Completed; Phase 2; Phase 1

Conditions: Coronary Artery Disease; Angina Refractory; Ischemia; Cardiovascular Diseases; Heart Diseases

Treatments: Biological: AdVEGFXC1

Study type: Interventional

Funder types: Industry

Identifiers

NCT04125732

XC001-1001

Details and patient eligibility

About

The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options. Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis (revascularization).

Full description

This is a Phase 1/2, first-in-human, multicenter, open-label, single arm dose escalation trial of XC001. Approximately 12 subjects (N=3 per cohort) who have refractory angina will be enrolled into 4 ascending dose groups, followed by an expansion of the highest tolerated dose with 32 additional subjects. XC001 will be administered by a transthoracic epicardial procedure. Safety will be the focus for the initial 6 months after XC001 administration followed by one safety focused telephone evaluation at Month 12.

Enrollment: 41 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males and females, age 18 to 80 years
• Diagnosis of chronic angina due to obstructive coronary artery disease that is refractory to drug therapy and unsuitable for revascularization via coronary artery bypass graft or percutaneous coronary intervention
• Angina class II-IV based on Canadian Cardiovascular Society Classification of Angina Pectoris
• Adequate hematologic (hemoglobin ≥ 10 g/dL, absolute neutrophil count > 1.2 × 10^3 per μL and platelet count ≥ 75,000 per μL), hepatic (alanine aminotransferase and aspartate aminotransferase ≤ 3 x ULN; total bilirubin ≤ 2 x ULN), and renal function (glomerular filtration rate > 29 mL/minute/1.73 m2)
• Adequate birth control if of child-bearing potential
• Must be willing and able to provide informed consent

Exclusion criteria

• ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI) not requiring revascularization, transmural myocardial infarction or cerebral vascular accident within the past 30 days
• New York Heart Association Function Class III or IV or left ventricular ejection fraction < 25% within the 6 weeks prior to the screening visit
• HbA1c ≥ 8.5%, SBP <90 or >180 mmHg, DBP >100 mmHg
• Other concurrent medical conditions that could jeopardize the safety of the subject or objectives of the study

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

41 participants in 4 patient groups

AdVEGFXC1 at 1x10^9 vp

Experimental group

Treatment:

Biological: AdVEGFXC1

AdVEGFXC1 at 1x10^10 vp

Experimental group

Treatment:

Biological: AdVEGFXC1

AdVEGFXC1 at 4x10^10 vp

Experimental group

Treatment:

Biological: AdVEGFXC1

AdVEGFXC1 at 1x10^11 vp

Experimental group

Treatment:

Biological: AdVEGFXC1